Shares in Zeneca sent 35p higher on Roche bid rumours
Saturday 12 April 1997
The bid rumour, the latest in a long series, emerged in a report in a Swiss newspaper which suggested that an offer worth pounds 21 to pounds 22 a share would be launched by Roche early next week. Cash, a weekly financial publication, claimed the two companies were in talks and the Basle-based Roche planned to sell off Zeneca's agrochemicals and specialty chemicals operations, keeping only the drugs business.
Neither company would comment yesterday. A representative for Roche said: "We've heard the rumours before and we didn't comment then and we are not commenting now."
The Swiss company has substantial cash resources and is thought to be interested in making acquisitions, but analysts played down the latest twist to what has become a long-running saga. James Dodwell, a pharmaceuticals watcher at Barclays de Zoete Wedd, said the two companies would fit together reasonably well. Roche had a lot of hospital products, while Zeneca's portfolio was strong in drugs targeted at GPs. Zeneca also had a strong franchise in cancer treatments, which Roche lacked, he suggested.
But he said: "Zeneca won't go freely. They want to remain independent and have said they are going to achieve 15 per cent per annum earnings growth for the next five years." Even for Roche, the possible $35bn price tag for the British group would be hard to digest, while the rating might be hard to justify.
The one piece of tangible good news yesterday for Zeneca, headed by chief executive Sir David Barnes, was that a US appeal court had upheld its patent rights over Nolvadex, still the most widely used treatment for breast cancer nearly quarter of a century after its launch. The appeal to the Federal court followed a challenge by Novopharm, a Canadian maker of generic drugs, which had been thrown out by a lower court in Maryland last April. Zeneca said the decision disposed of the proceedings instituted by Novopharm, which had wanted to produce a generic form of the drug.
The decision helps protect Zeneca's US patent until its expiry in 2002, although the company said it would continue patent infringement proceedings against two other companies, Mylan Pharmaceuticals and Pharmachemie, which have submitted applications for generic forms of the drug with America's Food and Drug Administration.
- 1 What happens to your body when you give up sugar?
- 2 Ed Miliband less influential than One Direction's Louis Tomlinson by official Doncaster power list
- 3 Japanese island overrun with cats after population explodes
- 4 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
California teacher appears to have hanged herself in her classroom
The City of the Monkey God: Archaeologists claim to have found city lost for 1,000 years in remote Honduran jungle
Ed Miliband less influential than One Direction's Louis Tomlinson by official Doncaster power list
Japanese island overrun with cats after population explodes
Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Durham Free School: 'Creationism taught at' free school facing closure
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Ukip would cut billions from Scottish budget to fund English tax cuts
End of the licence fee: BBC to back radical overhaul of how it is funded
Ukraine crisis: Top Chinese diplomat backs Putin and says West should 'abandon zero-sum mentality'
iJobs Money & Business
£15000 - £18000 per annum: Recruitment Genius: This is a great opportunity for...
£50000 - £60000 per annum + Excellent Salary: Austen Lloyd: An outstanding new...
£20000 - £21000 per annum + uncapped commission: SThree: As a graduate you are...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...